%0 Journal Article
%T 浅谈POCT及硫氧还蛋白还原酶活性检测在肿瘤领域的应用与进展<br>Discussion of the Applications and Progress of POCT and Thioredoxin Reductase Activity Testing (TrxR) in the Field of Oncology
%A 相宁
%A 张磊
%A 曾慧慧
%J Medical Diagnosis
%P 25-34
%@ 2164-5418
%D 2016
%I Hans Publishing
%R 10.12677/MD.2016.61006
%X 目的：通过对日立7600-110全自动生化仪和日立7170 s全自动生化分析仪测定结果比对，探讨不同仪器间天门冬氨酸氨基恶性肿瘤已成为我国最常见的导致死亡的疾病。由于病因与发病机制复杂，且缺乏早期诊断的特异性指标，导致诊断和治疗滞后，病死率极高。肿瘤标志物对于肿瘤的早期发现具有重要的提示意义，但目前肿瘤标志物检测大多依赖于专业实验室，成本高，检测周期长，且在医疗资源匮乏地区难以推广。近期新兴的POCT检验模式发展迅猛，因其设备便携，获得结果迅速且操作简单，故有利于人群中肿瘤标志物的筛查。硫氧还蛋白还原酶(TrxR)活性检测，是一种新型的肿瘤标志物检测，其在体内的表达和活性水平在一定程度上反应了体内细胞的异常增生程度。因此，POCT和TrxR活性检测的联合应用将有望成为癌症预防的新策略。<br />
Malignant tumors are the most common lethal diseases in China. Because of the complexity of carci-nogenesis and the lack of specific markers for early diagnosis, so delayed cancer diagnosis and treatment in clinic has a very high mortality rate. Tumor marker has important significance for early screening of carcinoma. However, the current biomarker detections for neoplasm mostly depend on the professional laboratories where it is of high-cost and difficult to extend such assay service in those medically challenged places. Recently point-of-care testing (POCT) has been rapidly developed. Due to its good portability, fast results and easy operation, it is beneficial for cancer screening in human population. Thioredoxin reductase (TrxR) is a novel tumor marker whose expression and activity reflect the extent of abnormal cellular proliferation to some degree. Overall, the combined application of POCT and TrxR activity assay may be a promising strategy for cancer prevention.
%K 恶性肿瘤，肿瘤标志物，POCT，硫氧还蛋白还原酶(TrxR)活性检测<br>Malignant Tumors
%K Tumor Marker
%K POCT
%K TrxR Activity Testing
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=17254